Trials / Completed
CompletedNCT04177680
Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia
Pharmacodynamic Effects of a Free-fatty Acid Formulation of Omega-3 Pentaenoic Acid to ENHANCE Efficacy in Adults With Hypertriglyceridemia: The ENHANCE-IT Trial
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Matinas BioPharma Nanotechnologies, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Pharmacodynamic effects of MAT9001 compared to Vascepa in adults with hypertriglyceridemia
Detailed description
An open-label, randomized, crossover study to assess the pharmacodynamic effects of MAT-9001, an omega-3 free fatty acid compared to Vascepa (icosapent ethyl) on triglycerides and other lipoprotein lipids in men and women with elevated triglycerides.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Omega 3 pentaenoic acid | Encapsulated omega-3 pentaenoic acid |
| DRUG | icosapent ethyl | Encapsulated omega-3 acid ethyl esters |
Timeline
- Start date
- 2020-06-03
- Primary completion
- 2020-11-27
- Completion
- 2021-01-18
- First posted
- 2019-11-26
- Last updated
- 2022-03-04
- Results posted
- 2022-03-04
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04177680. Inclusion in this directory is not an endorsement.